Ultima-Tesamorelin 5mg

Manufacturer: Ultima Pharmaceuticals

Pharmaceutical name: Tesamorelin

Pack: 1 vial (5 mg)

Products are being shipped without brand labeling for security purposes.

 

 

Tesamorelin (Tesamorelin) is formulated with growth hormone-releasing factor (GRF).

 

Tesamorelin is utilized to diminish excess abdominal fat resulting from certain HIV medications. This condition is referred to as lipodystrophy (LYE-poe-DIS-troe-fee).

 

Tesamorelin is not intended for weight loss and should not be employed for obesity treatment.

 

Tesamorelin (Tesamorelin for injection) is approved for the reduction of excess stomach fat in HIV-infected individuals with lipodystrophy.

 

Limitations of Use:

As the long-term cardiovascular safety and potential cardiovascular benefits of Tesamorelin treatment have not been evaluated, careful assessment should be given to the continuation of Tesamorelin therapy in patients who do not demonstrate a clear efficacy response, which is determined by the degree of reduction in visceral adipose tissue measured by waist circumference or CT scan.

Tesamorelin is not approved for weight loss management (weight neutral effect).

There is no evidence to support enhanced adherence to antiretroviral therapies in HIV-positive individuals receiving Tesamorelin.

 

General Dosing Information

The suggested dose of Tesamorelin is 2 mg administered subcutaneously once daily.

 

The recommended site for injection is the abdomen. Injection sites should be alternated among different areas of the abdomen. Avoid injecting into scar tissue, bruises, or the navel.

 

Reconstitution Procedure

Tesamorelin must be reconstituted using the diluent that comes with the product.

Reconstitute the 2 mg vial of Tesamorelin with 2.1 mL of diluent. Gently roll the vial in your hands for 30 seconds to mix; do not shake.

Comprehensive instructions for reconstituting Tesamorelin are included in the INSTRUCTIONS FOR USE leaflet found inside the boxes with Tesamorelin and the diluent.

 

Administer Tesamorelin right after reconstitution and dispose of any unused solution. If not used immediately, the reconstituted Tesamorelin solution should be discarded. Do not freeze or refrigerate the reconstituted solution.

 

Administration

The reconstituted Tesamorelin solution should always be visually inspected for particulate matter and discoloration prior to administration, as long as the solution and container allow it. Tesamorelin must only be injected if the solution is clear, colorless, and free of particulate matter.

 

Tesamorelin should be administered subcutaneously into the skin of the abdomen. Injection sites should be rotated to different areas of the abdomen. Avoid injecting into scar tissue, bruises, or the navel.